http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016104704-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83a32fd32d1badbaaee97b1de6dfcd85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca5c747d93a2a823c41948e42d9c3a95 |
| publicationDate | 2016-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016104704-A |
| titleOfInvention | Antitumor agent |
| abstract | A combination therapy useful as a malignant tumor therapeutic agent is provided. The present inventors have confirmed that an enhanced malignant tumor therapeutic effect can be obtained by using bendamustine in combination with sepantronium, and have completed the present invention. A composition for malignant tumor treatment containing sepantronium as an active ingredient, characterized in that it is used for combination therapy with bendamustine of the present invention, various malignant tumors such as lymphoma, leukemia, multiple myeloma and solid cancer, It can be used especially for the treatment of non-Hodgkin lymphoma. [Selection] Figure 1 |
| priorityDate | 2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.